------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

InvestBio Ventures Invests $14 Million in The Vaccine Company to
Initiate its Phase III Clinical Trial for the PR1 Vaccine for
Leukemia

InvestBio Ventures -- The Vaccine Company, L.P., an InvestBio
Ventures Partnership, announced today that it has raised $14 million
of a planned $20 million investment in The Vaccine Company (TVC).
This first stage of the investment in TVC was completed on October
17, 2005. InvestPrivate, Inc. acted as the placement agent for the
offering.

TVC was formed in July 2003 to commercialize the PR1 vaccine
that is being developed at the MD Anderson Cancer Center at The
University of Texas. The funding will help The Vaccine Company
initiate its pivotal Phase III clinical trial using the PR1 vaccine
to treat patients with acute myelogenous leukemia (AML).

On September 19, 2005, The Vaccine Company received approval
from the
Department of Health and Human Services to begin its clinical trial
in AML.
TVC is expected to begin the Phase III study in AML in the first
quarter of
2006. TVC also has announced plans to request approval to begin a
Phase II
clinical trial to treat MDS in the near future, pending completion
of the
Series C financing.
Said Scott Mathis, CEO and Chairman of InvestBio: "The Vaccine
Company is
a biotech company with significant potential. We're thrilled that
we were
able to help lead the effort to secure this financing. This is an
exciting
deal on many fronts and embodies our philosophy of 'Get Healthy, Get
Wealthy,'
helping the advancement of leukemia research for patients and
investors alike.
We and our investors in the InvestBio Ventures-The Vaccine Company,
L.P. fund
are very proud of helping finance the clinical trials of what may
be, if
successful, a breakthrough in leukemia treatment."
Ron Garren, M.D., Chairman and Founder of The Vaccine Company
stated, "We
are excited about the clinical potential of the PR1 vaccine and look
forward
to initiating the Phase III trial in AML."
InvestBio Ventures is an operation of InvestBio, Inc, an
organization that
seeks to help investors and its customers capitalize on business and
investment opportunities in the biotechnology sector.
InvestPrivate, Inc., a registered broker-dealer (member NASD,
SIPC, SIA),
under common control with InvestBio, Inc., served as the placement
agent in
connection with this investment.

About InvestPrivate:
InvestPrivate, Inc. (www.investprivate.com) (member NASD, SIPC,
SIA), founded in 1999 and headquartered in New York, is a boutique
investment
brokerage firm that specializes in the biotechnology sector,
offering access
to venture capital, private equity investments and publicly traded
securities.
InvestPrivate, Inc. is a holding of Diversified Biotech Holdings
Corp.
(DBHC), a diversified organization that seeks to help investors and
its
customers capitalize on business and investment opportunities in the
biotechnology sector.

About InvestBio:
InvestBio, Inc. (www.investbio.com) serves as a central resource
for biotech investors seeking unbiased information and access to
investment
opportunities. InvestBio, Inc. identifies, selects, structures and
manages
biotechnology-related venture capital, private equity and hedge fund
investments for qualified individual accredited investors.
InvestBio, Inc. is a holding of Diversified Biotech Holdings
Corp. (DBHC),
a diversified organization based in New York City that seeks to help
investors
and its customers capitalize on business and investment
opportunities in the
biotechnology sector.

Important Notes:
The Private Securities Litigation Reform Act of 1995 provides a
safe
harbor for forward-looking statements. This press release may
contain certain
statements of a forward-looking nature relating to future events or
future
business performance. Any such statements that refer to the Company's
estimated or anticipated future results or other non-historical
facts are
forward-looking and reflect the Company's current perspective of
existing
trends and information. These statements involve risks and
uncertainties that
cannot be predicted or quantified and, consequently, actual results
may differ
materially from those expressed or implied by such forward-looking
statements.
The forward-looking statements speak only as of the date of this
release. The
Company undertakes no obligation to update publicly any forward-
looking
statement, whether as a result of new information, future events or
otherwise.
For more information, please contact Scott L. Mathis, InvestBio,
Inc., at
(212) 739-7676 or info@investbio.com.

1999 - 2005. InvestBio, Inc., a subsidiary of Diversified
Biotech Holdings
Corporation. This information is not intended for use without
professional
advice.

SOURCE InvestPrivate/InvestBio

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech